# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers

> **NCT01620463** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 32 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** liraglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01620463
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2003-03
- **Final completion:** 2003-03
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01620463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01620463, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01620463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*